Alzheimer's drug registry aims to uncover who really benefits

NCT ID NCT05925621

Recruiting now Knowledge-focused Sponsor: Beth Israel Deaconess Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 500 people with early Alzheimer's who are receiving anti-amyloid antibody therapy (like lecanemab) in routine care. Researchers will compare their cognitive decline to historical data and track side effects. The goal is to learn how well these drugs work in the real world and who might be at higher risk for complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lecanemab (anti-amyloid antibody)
What this could lead to: If successful, this registry could clarify how well anti-amyloid antibodies slow Alzheimer's progression and which patients benefit most.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.